

QUICK REVIEW ON THE MERS-COV, SARS-COV AND SARS-COV-2 CORONAVIRUS

Sukrit Srivastava¹, Sailesh Narayan²

¹Department of Biotechnology & Life Sciences, Mangalayatan University, Aligarh, UP

²Faculty of Health Sciences, Usha Martin University, Ranchi, Jharkhand

Email: sukrit.srivastava@mangalayatan.edu.in

INTRODUCTION

The human coronaviruses was first identified in mid 1960s. Coronavirus are subgrouped in alpha, beta, gamma & delta. Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV and SARS-CoV-2) & Middle East Respiratory Syndrome Coronavirus (MERS-CoV) are included in Beta coronaviruses (Sharifi-Mood 2015; Ksiazek et al., 2003, Cho et al., 2016., Kim et al., 2015). Coronaviruses are viruses that belong to the subfamily of Coronavirinae in the family of Coronaviridae, cause the common cold and severe acute respiratory syndrome; they are well known to cause disease in humans and animals including himalayan palm civets, raccoon, monkeys, dogs, cats, dogs, and rodents. MERS-CoV is genetically distinct from the SARS-CoV and SARS-CoV-2, which has emerged as a pandemic in the last decade and appears to behave differently (Baseler et al., 2015; Yang et al., 2015). Incidence of Human coronavirus infection among infants is highest during the winter and early spring seasons. Middle East Respiratory Syndrome (MERS) is a syndrome affecting upper respiratory system and is caused by Middle East Respiratory Syndrome Coronavirus (MERS-CoV). MERS cases high fever, chills, chest pain, bodyaches, cough, breathing problem, sore throat, diarrhoea, renal failure, pneumonia, nausea/vomiting and running nose. First case of MERS to human was reported in year 2012 in Saudi Arabia. After 2012 MERS-CoV infection has been reported from 27 countries only within 4 years (WHO report: 2016). Till present three MERS outbreaks have taken place in Saudi Arabia (2013, 2014) and in South Korea (2015) (Assiri et al., 2013; Oboho et al., 2015; Park et al., 2015). Outbreak reported in South Korea was reported to have fatality rate as high as 40%, and it also involved spreading of MERS while hospital-to-hospital transit of patients. High attack rate and easy spreading means has put MERS disease at risk of an epidemic (Kim et al., 2015; Ki., 2015; WHO Emergencies preparedness, response, 2015). Till date no specific vaccine is available against MERS. There is an urgent need for specific and safe MERS vaccine keeping in mind the steep increase of MERS cases and its high mortality rate. As far now the pathogenesis of MERS-CoV is largely unknown. Hence, an immunoinformatics approach to thoroughly study and screen potential immunogenic proteins from available proteome sequence data of MERS-CoV is very essential for vaccine development. SARS started off in the Guangdong Province in southern China in the month of November 2002. Eventually it reached Hong Kong, from where it rapidly spread around the world, infecting people in 37 countries (Hsieh et al., 2015., Kong et al., 2015). Severe acute respiratory syndrome coronavirus (SARSCoV) causes a severe form of upper respiratory track disorder called the Severe acute respiratory syndrome (SARS). The SARS infection is highly contagious and is prominently characterized by breathing difficulties, high fever, dry cough, and pneumonia. SARS is endemic in southern China. In the year 2003, the SARS outbreak in south China caused 8098 people sick and 774 dead. Eventually, SARS has now reported to spread around the world, infecting people in 37 countries (Zhong et al, 2003; Booth et al., 2003; Leung et al., 2003; CDC report; 2018). Even though there is an urgent need to develop a specific SARS vaccine, till date there is no specific and safe vaccine against SARS. Pathogenesis mechanism of SARS-CoV and SARS-CoV-2 being still largely unknown the immunoinformatics approach to design and develop an epitope-based specific vaccine against SARS would be an essential step forward.

The MERS-CoV, SARS-CoV and SARS-CoV-2 Coronavirus

The proteome of MERS-CoV consists of several vaccine candidate proteins as well as drug target proteins. These proteins are mostly involved in infection and pathogenesis process of the MERS-CoV to human host cells. The Spike (S) glycoprotein, in particular, its receptor-binding domain (RBD) is involved in the virus-host cell interaction (Wang et al., 2015). Envelope (E) protein plays an essential role in the host cell recognition (Xie et al., 2017). Nucleocapsid (N) protein is involved in the RNA binding, during ribonucleocapsid formation by MERS-CoV (Wang et al., 2015). Membrane (M) protein has important role involving its interferon (IFN)-antagonizing properties and reducing IFN levels in infected patients (Lui

et al., 2016). Open reading frame (ORF) proteins play critical roles in viral infection and the pathogenesis. Mutational studies on ORFs (ORF3, -4a, -4b, and -5) proteins has indicated that ORFs have major implications in viral infection causing disruption of host cell, disordered interferon (IFN) pathway, and abrupt inflammation (Menachery et al., 2017). Proteins ORF1a (4P16) and ORF1ab (4WUR) are papain-like proteases (PL(pro)) and are involved in viral infection, hence these proteins are potential target for the development of antiviral drugs (Lei et al., 2014). The papain-like proteases facilitate infection by their proteolytic, deubiquitinating activity, and deISGylating activity suppressing the innate immune response from the host cell. The ORF1a (4RSP) protein is a protease (3CLpro) and it provides proteolytic activity during viral infection and replication (Tomar et al., 2015; Lei et al., 2016). Protein ORF 1ab (5WWP) is a helicase protein of MERS-CoV, this protein is one of the most conserved proteins amongst nidoviruses. Protein ORF8b is a highly conserved and while infection it is involved in inducing various immune response (Lu et al., 2015). All the above proteins of MERS-CoV are critically involved in pathogenesis of the virus to the human cells. Hence, are chosen to screen out potential epitopes to design Multi-Epitope Vaccines (MEVs) and Multi-Patch vaccine against MERS-Cov, SARS-CoV and SARS-CoV-2. The designed and proposed MEVs in this study are composed of Cytotoxic T lymphocyte and Helper T lymphocyte (CTL and HTL) epitopes. Both the CTL and HTL MEVs also contain overlapping regions of linear B cell epitopes. Both the MEVs were designed to have human β Defensin 2 and human β Defensin 3 as adjuvants for the purpose to enhance the immunogenic response (Duits et al., 2003; Wilson et al., 2013). The proteome of SARS-CoV and SARS-CoV-2 consists of several important drug target and vaccine candidate proteins. The present study covers screening of potential epitopes from eleven different SARS-CoV and SARS-CoV-2 proteins. All the chosen proteins are critically involved in virus-host interaction and pathogenesis. The Spike (S) protein of SARS-CoV and SARS-CoV-2 is involved in membrane fusion and viral entry into the human host cell (Du, et al., 2009; Liao, et al., 2015). The Envelope (E) protein is involved in anchoring and hence plays a determining role in virus-human host cell interaction and viral pathogenesis (Jimenez-Guardeño, et al., 2014). The membrane (M) protein is important for assembly and budding of viral particles and hence is a crucial protein for viral pathogenesis (Voß, et al., 2009). The nucleocapsid (N) protein is involved in packaging of the viral genome into a helical ribonucleocapsid, hence are involved in viral self-assembly and pathogenesis (Wei, et al., 2012; Chang, et al., 2014). The ORF (Open Reading Frame) 3a protein plays an important role in viral replication and hence is a potential target for drug and vaccine design (Lu, et al., 2009; Åkerström, et al., 2007; Zhong, et al., 2006). The ORF 3b protein is involved in the upregulation of transcriptional activity during pathogenesis and hence 3b protein is a potential drug and vaccine design target (Åkerström, et al., 2007; Varshney, et al., 2012). The ORF 7a protein is involved in the viral replication cycle (Åkerström, et al., 2007; Vasilenko, et al., 2010). The ORF 7b protein is involved in virus replication as well as it enhances virulence (Pfefferle, et al., 2009; DeDiego, et al., 2008). The ORF 8a protein enhances viral replication as well as it also induces host cell apoptosis (Chen, et al., 2007). The ORF 8b protein plays important role in viral replication and it also induces DNA synthesis (Law, et al., 2006). The ORF 9b protein enhances pathogenesis by suppressing innate immunity (Shi, et al., 2014). All the above-discussed eleven proteins of SARS-CoV and SARS-CoV-2 play important role in either viral proliferation or human host cell pathogenesis hence are potential targets for drug and vaccine design and were chosen for further study.

CONCLUSION

In the present study, we conclude that a more specific and targeted strategy to design vaccine against Coronaviruses is required. The Multi-Patch design vaccine against MERS-CoV, SARS-CoV and SARS-CoV-2 have been validated for stable complex formation with ectodomain of TLR3. Hence the novel Multi-Patch Vaccine design by utilizing antigenic patches (Ag-Patches) could be a potential candidate to combat MERS-CoV, SARS-CoV and SARS-CoV-2, with higher effectiveness, higher specificity and larger human population coverage.

REFERENCES

- Åkerström, S., Mirazimi, A. and Tan, Y.J., (2007). Inhibition of SARS-CoV replication cycle by small interference RNAs silencing specific SARS proteins, 7a/7b, 3a/3b and S. *Antiviral research*, 73(3), pp.219-227.
- Assiri, A., McGeer, A., Perl, T.M., Price, C.S., Al Rabeeah, A.A., Cummings, D.A., Alabdullatif, Z.N., Assad, M., Almulhim, A., Makhdoom, H. and Madani, H., (2013). Hospital outbreak of Middle East respiratory syndrome coronavirus. *N Engl J Med*, (369), pp.407-416.

- Baseler, L.J., Falzarano, D., Scott, D.P., Rosenke, R., Thomas, T., Munster, V.J., Feldmann, H. and de Wit, E., (2016) 'An acute immune response to Middle East respiratory syndrome coronavirus replication contributes to viral pathogenicity', *The American journal of pathology*, 186(3), pp.630-638.
- Booth, C. M., Matukas, L. M., Tomlinson, G. A., Rachlis, A. R., Rose, D. B., Dwosh, H. A., & Detsky, A. S., (2003). "Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area". *Jama*, 289 (21), 2801-2809.
- CDC Report (2018); Severe Acute respiratory syndrome (SARS), SARS Basics Fact Sheet; Available at: <https://www.cdc.gov/sars/about/fs-sars.html> (Accessed date: 15 November 2018)
- Chang, C.K., Hou, M.H., Chang, C.F., Hsiao, C.D. and Huang, T.H., (2014). The SARS coronavirus nucleocapsid protein—forms and functions. *Antiviral research*, 103, pp.39-50.
- Chen, X., Zaro, J.L. and Shen, W.C., (2013). Fusion protein linkers: property, design and functionality. *Advanced drug delivery reviews*, 65(10), pp.1357-1369.
- Chou PY, Fasman GD. (1978). Prediction of the secondary structure of proteins from their amino acid sequence. *Adv EnzymolRelat Areas Mol Biol* 47:45-148.
- DeDiego, M.L., Pewe, L., Alvarez, E., Rejas, M.T., Perlman, S. and Enjuanes, L., (2008). Pathogenicity of severe acute respiratory coronavirus deletion mutants in hACE-2 transgenic mice. *Virology*, 376(2), pp.379-389.
- Du, L., He, Y., Zhou, Y., Liu, S., Zheng, B.J. and Jiang, S., (2009). The spike protein of SARS-CoV—a target for vaccine and therapeutic development. *Nature Reviews Microbiology*, 7(3), p.226.
- Duits, L.A., Nibbering, P.H., Strijen, E., Vos, J.B., Manesse-Lazeroms, S.P., Sterkenburg, M.A. and Hiemstra, P.S., (2003). Rhinovirus increases human β -defensin-2 and-3 mRNA expression in cultured bronchial epithelial cells. *Pathogens and Disease*, 38(1), pp.59-64.
- Hsieh, Y. H. (2015). "Middle East Respiratory Syndrome Coronavirus (MERS-CoV) nosocomial outbreak in South Korea: insights from modeling". *PeerJ*, 3, e1505.
- Jimenez-Guardeño, J.M., Nieto-Torres, J.L., DeDiego, M.L., Regla-Nava, J.A., Fernandez-Delgado, R., Castaño-Rodríguez, C. and Enjuanes, L., (2014). The PDZ-binding motif of Severe Acute respiratory syndrome coronavirus envelope protein is a determinant of viral pathogenesis. *PLoS pathogens*, 10(8), p.e1004320.
- Ki, M., (2015). MERS outbreak in Korea: hospital-to-hospital transmission. *Epidemiol Health*. (2015; 37: e(2015033).
- Kim, J. I., Kim, Y. J., Lemey, P., Lee, I., Park, S., Bae, J. Y., & Kim, D. W. (2015). "The recent ancestry of Middle East respiratory syndrome coronavirus in Korea has been shaped by recombination". *Scientific reports*, 6, 18825-18825.
- Kong, J., Shi, Y., Wang, Z., & Pan, Y. (2015) "Interactions among SARS-CoV accessory proteins revealed by bimolecular fluorescence complementation assay". *Acta Pharmaceutica Sinica B*, 5(5), 487-492.
- Ksiazek, T. G., Erdman, D., Goldsmith, C. S., Zaki, S. R., Peret, T., Emery, S., & Anderson, L. J. (2003). A novel coronavirus associated with severe acute respiratory syndrome. *New England Journal of Medicine*, 348(20), 1953-1966.
- Law, P.Y.P., Liu, Y.M., Geng, H., Kwan, K.H., Waye, M.M.Y. and Ho, Y.Y., (2006). Expression and functional characterization of the putative protein 8b of the severe acute respiratory syndrome-associated coronavirus. *FEBS letters*, 580(15), pp.3643-3648.
- Lei, J. and Hilgenfeld, R., (2016). Structural and mutational analysis of the interaction between the Middle-East respiratory syndrome coronavirus (MERS-CoV) papain-like protease and human ubiquitin. *Virologica Sinica*, 31(4), pp.288-299.
- Lei, J., Mesters, J.R., Drosten, C., Anemüller, S., Ma, Q. and Hilgenfeld, R., (2014). Crystal structure of the papain-like protease of MERS coronavirus reveals unusual, potentially druggable active-site features. *Antiviral research*, 109, pp.72-82.
- Leung, T. F., Wong, G. W. K., Hon, K. L. E., & Fok, T. F., (2003) "Severe Acute respiratory syndrome (SARS) in children: epidemiology, presentation and management". *Paediatric respiratory reviews*, 4(4), 334-339.
- Liao, Y., Zhang, S.M., Neo, T.L. and Tam, J.P., (2015). Tryptophan-dependent membrane interaction and heteromerization with the internal fusion peptide by the membrane proximal external region of SARS-CoV spike protein. *Biochemistry*, 54(9), pp.1819-1830.
- Lu, B., Tao, L., Wang, T., Zheng, Z., Li, B., Chen, Z., Huang, Y., Hu, Q. and Wang, H., (2009). Humoral and cellular immune responses induced by 3a DNA vaccines against Severe Acute respiratory syndrome (SARS) or SARS-like coronavirus in mice. *Clinical and Vaccine Immunology*, 16(1), pp.73-77.

- Lu, R., Zou, L., Wang, Y., Zhao, Y., Zhou, W., Wu, J., Wang, W., Wu, G., Ke, C. and Tan, W., (2015). Sequencing and Phylogenetic Analyses of Structural and Accessory Proteins of Middle East Respiratory Syndrome Coronavirus from the First Imported Case in China, (2015. Chinese journal of virology, 31(4), pp.333-340.
- Lui, P.Y., Wong, L.Y.R., Fung, C.L., Siu, K.L., Yeung, M.L., Yuen, K.S., Chan, C.P., Woo, P.C.Y., Yuen, K.Y. and Jin, D.Y., (2016). Middle East respiratory syndrome coronavirus M protein suppresses type I interferon expression through the inhibition of TBK1-dependent phosphorylation of IRF3. *Emerging microbes & infections*, 5(4), p.e39.
- Menachery, V.D., Mitchell, H.D., Cockrell, A.S., Gralinski, L.E., Yount, B.L., Graham, R.L., McAnarney, E.T., Douglas, M.G., Scobey, T., Beall, A. and Dinnon, K., (2017). MERS-CoV Accessory ORFs Play Key Role for Infection and Pathogenesis. *mBio*, 8(4), pp.e00665-17.
- Oboho, I.K., Tomczyk, S.M., Al-Asmari, A.M., Banjar, A.A., Al-Mugti, H., Aloraini, M.S., Alkhalidi, K.Z., Almohammadi, E.L., Alraddadi, B.M., Gerber, S.I. and Swerdlow, D.L., (2015). (2014 MERS-CoV outbreak in Jeddah—a link to health care facilities. *New England Journal of Medicine*, 372(9), pp.846-854.
- Park, J.W., Lee, K.J., Lee, K.H., Lee, S.H., Cho, J.R., Mo, J.W., Choi, S.Y., Kwon, G.Y., Shin, J.Y., Hong, J.Y. and Kim, J., (2017). Hospital Outbreaks of Middle East Respiratory Syndrome, Daejeon, South Korea, (2015. *Emerging infectious diseases*, 23(6), p.898.
- Pfefferle, S., Krähling, V., Ditt, V., Grywna, K., Mühlberger, E. and Drosten, C., (2009). Reverse genetic characterization of the natural genomic deletion in SARS-Coronavirus strain Frankfurt-1 open reading frame 7b reveals an attenuating function of the 7b protein in-vitro and in-vivo. *Virology journal*, 6(1), p.131.
- Sharifi-Mood, B. (2015). Middle East Respiratory Syndrome Coronavirus. *Biotechnology and Health Sciences*, pp: 2(1).
- Tomar, S., Johnston, M.L., John, S.E.S., Osswald, H.L., Nyalapatla, P.R., Paul, L.N., Ghosh, A.K., Denison, M.R. and Mesecar, A.D., (2015). Ligand-induced Dimerization of Middle East Respiratory Syndrome (MERS) Coronavirus nsp5 Protease (3CLpro) IMPLICATIONS FOR nsp5 REGULATION AND THE DEVELOPMENT OF ANTIVIRALS. *Journal of Biological Chemistry*, 290(32), pp.19403-19422.
- Varshney, B., Agnihotram, S., Tan, Y.J., Baric, R. and Lal, S.K., (2012). SARS coronavirus 3b accessory protein modulates transcriptional activity of RUNX1b. *PloS one*, 7(1), p.e29542.
- Vasilenko, N., Moshynskyy, I. and Zakhartchouk, A., (2010). SARS coronavirus protein 7a interacts with human Ap 4 A-hydrolase. *Virology journal*, 7(1), p.31.
- Voß, D., Pfefferle, S., Drosten, C., Stevermann, L., Traggiai, E., Lanzavecchia, A. and Becker, S., (2009). Studies on membrane topology, N-glycosylation and functionality of SARS-CoV membrane protein. *Virology journal*, 6(1), p.79.
- Wang L, Shi W, Joyce MG, Modjarrad K, Zhang Y, Leung K, et al. (2015). Evaluation of candidate vaccine approaches for MERS-CoV. *Nat Commun.*; 6:7712. PMID: 26218507
- Wei, W.Y., Li, H.C., Chen, C.Y., Yang, C.H., Lee, S.K., Wang, C.W., Ma, H.C., Juang, Y.L. and Lo, S.Y., (2012). SARS-CoV nucleocapsid protein interacts with cellular pyruvate kinase protein and inhibits its activity. *Archives of virology*, 157(4), pp.635-645.
- Wilson, S.S., Wiens, M.E. and Smith, J.G., (2013). Antiviral mechanisms of human defensins. *Journal of molecular biology*, 425(24), pp.4965-4980.
- World Health Organization. (2015) Emergencies preparedness, response: coronavirus infections. Available at: <http://www.who.int/csr/don/25-october-2015-mers-korea/en/> (Accessed date: 15 November 2018).
- Xie, Q., He, X., Yang, F., Liu, X., Li, Y., Liu, Y., Yang, Z., Yu, J., Zhang, B. and Zhao, W., (2018). Analysis of the genome sequence and prediction of B-cell epitopes of the envelope protein of Middle East respiratory syndrome coronavirus. *IEEE/ACM Transactions on Computational Biology and Bioinformatics (TCBB)*, 15(4), pp.1344-1350.
- Yang, X. L., Hu, B., Wang, B., Wang, M. N., Zhang, Q., Zhang, W., & Wang, L. F. (2015). "Isolation and characterization of a novel bat coronavirus closely related to the direct progenitor of SARS coronavirus". *Journal of virology*, JVI-02582.
- Zhong, N. S., Zheng, B. J., Li, Y. M., Poon, L. L. M., Xie, Z. H., Li, P. H., & Guan, Y. (2003). "Epidemiological and aetiological studies of patients with Severe Acute respiratory syndrome (SARS) from Guangdong in February (2003". *Lancet*, 362(9393), 1353-1358.